However, the GLI1 inhibitor blocked the Hh pathway more effectively than the SMO inhibitor, likely because cancer cells exhibit “non-canonical” activation of the Hh pathway, which is caused by alternative signaling pathways (ErbB receptors, NF-κB, Wnt, and Notch) [58]. This evidence concerns the gene GLI1 and cancer.